Flunitrazepam oxidative metabolism in human liver microsomes: Involvement of CYP2C19 and CYP3A4

Xenobiotica

Volumn 29, Issue 10, 1999, Pages 973-986

  Coller, J K ^a   Somogyi, A A ^a   Bochner, F ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYFLUNITRAZEPAM; ACETONITRILE; ANTIBODY; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ENZYME; FLUNITRAZEPAM; N,N DIMETHYLFORMAMIDE; NORFLUNITRAZEPAM; PHENACETIN O DEETHYLASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG METABOLISM; ENZYME KINETICS; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MALE; TECHNIQUE;

ACETONITRILES; ADULT; AGED; ANTIBODIES, MONOCLONAL; ARYL HYDROCARBON HYDROXYLASES; BENZOFLAVONES; CYTOCHROME P-450 ENZYME SYSTEM; DIMETHYLFORMAMIDE; ENZYME ACTIVATION; FEMALE; FLUNITRAZEPAM; GENOTYPE; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; SOLVENTS;

EID: 0032700187     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238056     Document Type: Article

References (21)

1. ANDERSSON, T., MINERS, J. O., VERONESE, M. E. and BIRKETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 331-337.
2. CANO, J. P., 1983, Clinical pharmacokinetics of benzodiazepines. In M. Tiengo and M. J. Cousins (eds), Pharmacological Basis of Anesthesiology, 3rd edn (New York: Raven), pp. 44-55.
3. CHAURET, N., GAUTHEIR, A. and NICOLL-GRIFFITH, D. A., 1998, Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metabolism and Disposition, 26, 1-4.
4. COLLER, J. K., SOMOGYI, A. A. and BOCHNER, F., 1997, Association between CYP2C19 genotype and proguanil oxidative polymorphism. British Journal of Clinical Pharmacology, 43, 659-660.
5. COLLER, J. K., SOMOGYI, A. A. and BOCHNER, F., 1998, Quantification of flunitrazepam's oxidative metabolites, 3-hydroxyflunitrazepam and desmethylflunitrazepam, in hepatic microsomal incubations by high-performance liquid chromatography. Journal of Chromatography B, 719, 87-92.
6. EAGLING, V. A., TIJA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107-114.
7. GRAHNEN, A., WENNERLUND, P., DAHLSTROM, B. and ECKERNAS, S.-A., 1991, Inter- and intra-individual variability in the concentration effect (sedation) relationship of flunitrazepam. British Journal of Clinical Pharmacology, 31, 89 92.
8. HEIM, M. and MEYER, U. A., 1990, Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet, 336, 529 32.
9. HICKMAN, D., WANG, J.-P. and UNADKAT, J. D., 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metabolism and Disposition, 26, 207-215.
10. LOWRY, O. H., ROSEBURG, N. J., FARR, A. L. and RANDALL, R. J., 1951, Measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
11. LUURILA, H., OLKKOLA, K. T. and NEUVONEN, P. J., 1996, Interaction between Erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacology and Toxicology, 78, 117 122.
12. MATTILA, M. A. K. and LARNI, H. M., 1980, Flunitrazepam: a review of its pharmacological properties and therapeutic use. Drugs, 20, 353 374.
13. MRAZ, J., JHEETA, P., GESCHER, A., HYLAND, R., THUMMEL., K. and THREADGILL, M. D., 1993, Investigation of the mechanistic basis of N,N-dimethylformamide toxicity. Metabolism of N,N-dimethylformamide and its deuterated isotopomers by cytochrome P450 2E1. Chemical Research in Toxicology, 6, 197-207.
14. NEWTON, D. J., WANG, R. W. and LU, A. Y. H., 1995, Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
15. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes, II. Solubilisation, purification and properties. Journal of Biological Chemistry, 234, 2374 2385.
16. SAN, L., TATO, J., TORRENS, M., CASTILLO, C., FARRE, M. and CAMI, J., 1993, Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification. Drug and Alcohol Dependence, 32, 281-286.
17. SCHWAB, G. E., RAUCY, J. L. and JOHNSON, E. F., 1988, Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-napthoflavone. Molecular Pharmacology, 33, 493-499.
18. TASSANEEYAKUL, W., MAHAMED, Z., BIRKETT, D. J., McMANUS, M. E., VERONESE, M. E., TURKEY, R. H., QUATTROCHI, L. C., GONZALEZ, F. J. and MINERS, J. O., 1992, Caffeine as a probe for human cytochromes P450: validation using cDNA expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics, 2, 173-183.
19. UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativily in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370-381.
20. ZANGER, U.M., VILBOIS, F., HARDWICK, J. P. and MEYER, U. A., 1988, Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry, 27, 5447-5454.
21. ZHANG, X.-J. and THOMAS, P. E., 1996, Erythromycin as a specific substrate for cytochrome P4503A isozymes and identication of a high-affinity erythromycin N-demethylase in adult female rats. Drug Metabolism and Disposition, 24, 23-27.